Literature DB >> 27910983

Investigation and intervention of autophagy to guide cancer treatment with nanogels.

Xudong Zhang1, Xin Liang, Jianjun Gu, Danfeng Chang, Jinxie Zhang, Zhaowei Chen, Yanqi Ye, Chao Wang, Wei Tao, Xiaowei Zeng, Gan Liu, Yongjun Zhang, Lin Mei, Zhen Gu.   

Abstract

Cancer cells use autophagy to resist poor survival environmental conditions such as low PH, poor nutrients as well as chemical therapy. Nanogels have been used as efficient chemical drug carriers for cancer treatment. However, the effect of nanogels on autophagy is still unknown. Here, we used Rab proteins as the marker of multiple trafficking vesicles in endocytosis and LC3 as the marker of autophagy to investigate the intracellular trafficking network of Rhodamine B (Rho)-labeled nanogels. The nanogels were internalized by the cells through multiple protein dependent endocytosis and micropinocytosis. After inception by the cells, the nanogels were transported into multiple Rab positive vesicles including early endosomes (EEs), late endosomes (LEs), recycling endosomes (REs) and lipid droplets. Finally, these Rab positive vesicles were transported to lysosome. In addition, GLUT4 exocytosis vesicles could transport the nanogels out of the cells. Moreover, nanogels could induce autophagy and be sequestered in autophagosomes. The crosstalk between autophagosomes and Rab positive vesicles were investigated, we found that autophagosomes may receive nanogels through multiple Rab positive vesicles. Co-delivery of autophagy inhibitors such as chloroquine (CQ) and the chemotherapeutic drug doxorubicin (DOX) by nanogels blocked the autophagy induced by DOX greatly decreasing both of the volume and weight of the tumors in mice tumor models. Investigation and intervention of the autophagy pathway could provide a new method to improve the therapeutic effect of anticancer nanogels.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27910983     DOI: 10.1039/c6nr07866d

Source DB:  PubMed          Journal:  Nanoscale        ISSN: 2040-3364            Impact factor:   7.790


  7 in total

1.  Rab34 regulates adhesion, migration, and invasion of breast cancer cells.

Authors:  Lixiang Sun; Xiaohui Xu; Yongjun Chen; Yuxia Zhou; Ran Tan; Hantian Qiu; Liting Jin; Wenyi Zhang; Rong Fan; Wanjin Hong; Tuanlao Wang
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

2.  Intracellular Mechanistic Understanding of 2D MoS2 Nanosheets for Anti-Exocytosis-Enhanced Synergistic Cancer Therapy.

Authors:  Xianbing Zhu; Xiaoyuan Ji; Na Kong; Yunhan Chen; Morteza Mahmoudi; Xiaoding Xu; Li Ding; Wei Tao; Ting Cai; Yujing Li; Tian Gan; Austin Barrett; Zameer Bharwani; Hongbo Chen; Omid C Farokhzad
Journal:  ACS Nano       Date:  2018-03-12       Impact factor: 15.881

3.  Xiaoyaosan Exerts Antidepressant-Like Effect by Regulating Autophagy Involves the Expression of GLUT4 in the Mice Hypothalamic Neurons.

Authors:  Fu-Rong Yang; Xiao-Xu Zhu; Ming-Wang Kong; Xiao-Juan Zou; Qing-Yu Ma; Xiao-Juan Li; Jia-Xu Chen
Journal:  Front Pharmacol       Date:  2022-06-16       Impact factor: 5.988

4.  New findings of silica nanoparticles induced ER autophagy in human colon cancer cell.

Authors:  Fujing Wei; Yimin Wang; Zewei Luo; Yu Li; Yixiang Duan
Journal:  Sci Rep       Date:  2017-02-14       Impact factor: 4.379

Review 5.  Nanomedicine Reformulation of Chloroquine and Hydroxychloroquine.

Authors:  David M Stevens; Rachael M Crist; Stephan T Stern
Journal:  Molecules       Date:  2020-12-31       Impact factor: 4.411

6.  Co-delivery of docetaxel and bortezomib based on a targeting nanoplatform for enhancing cancer chemotherapy effects.

Authors:  Junpeng Nie; Wei Cheng; Yunmei Peng; Gan Liu; Yuhan Chen; Xusheng Wang; Chaoyu Liang; Wei Tao; Yinping Wei; Xiaowei Zeng; Lin Mei
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

7.  Mangiferin Enhanced Autophagy via Inhibiting mTORC1 Pathway to Prevent High Glucose-Induced Cardiomyocyte Injury.

Authors:  Jun Hou; Dezhi Zheng; Wenjing Xiao; Dandan Li; Jie Ma; Yonghe Hu
Journal:  Front Pharmacol       Date:  2018-04-17       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.